Masimo Corp. ((MASI)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Masimo Corp. is conducting a study titled ‘Investigation of Skin Pigmentation Effect on Performance of Masimo Pulse Oximetry (INSPIRE).’ The study aims to evaluate how skin pigmentation affects the performance of Masimo RD SET® SpO2 sensors, particularly in patients with hypoxemia in intensive care settings. This research is significant as it seeks to ensure the accuracy of pulse oximetry across diverse skin tones, which is crucial for patient safety and care.
The intervention being tested is the RD SET Sensor, a device used to measure blood oxygen levels. This sensor is being evaluated for its performance across different skin pigmentation levels to ensure consistent and reliable readings.
The study follows an interventional design with a sequential intervention model. There is no allocation or masking involved, and the primary purpose is categorized as ‘other,’ focusing on evaluating device performance rather than therapeutic outcomes.
The study began on February 23, 2024, with a primary completion date yet to be announced. The most recent update was submitted on July 31, 2025. These dates are important as they indicate the study’s progress and potential timeline for results, which can influence investor decisions.
This study update could impact Masimo’s stock performance by potentially enhancing investor confidence if the results demonstrate improved device accuracy. It also positions Masimo competitively within the medical device industry, especially if the study addresses a known gap in pulse oximetry performance across different skin tones.
The study is ongoing, with further details available on the ClinicalTrials portal.